SANUVAVE®

Healing today. Curing tomorrow.

Creating a brighter future by providing novel and cost effective solutions, focused on societal needs with the sole purpose of bettering lives everywhere

OTCQB: SNWV

August 2019

Forward-Looking Statement Disclaimer

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective.


Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements.

Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.



SANUWAVE Health

SANUWAVE Health (SNWV), Inc. is an emerging shockwave technology company focused on the development and commercialization of patented noninvasive, high-energy, acoustic focused, shockwaves for the repair and regeneration of tissue, musculoskeletal and vascular structures.





Investment Highlights & Recent Developments

Accomplishments in 2018

- Hired Shri Parikh, President Healthcare
- Received reimbursement tracking for DFU procedure
- Signed Premier Shockwave as the exclusive distributor for the VA and IHS
- Added Science Advisor, Dr. Perry Mayer
- JWC published a peer review article on SANUWAVE's 336 double blind study
- Added 15 countries to international distribution
- Signed with NFS to help finance equipment growth

Goals for 2019

- 100 US Placements; 300 certified users
- Reimbursement; finish with at least 10 million lives covered and paid by insurance
- Launch 2-3 domestic clinical studies
- Add 3-4 new countries
- Add Additional science advisors
- Add other key senior management hires




A Leader in Shockwave Technology Development and Commercialization

Patented, non-invasive devices for the repair and regeneration of:


- Skin
- Musculoskeletal tissue
- Vascular structures

Devices activate biologic signaling and angiogenic responses, producing:

- New vascularization
- Microcirculatory improvement
- Tissue regeneration



Growth factor upregulation





Global Wound Care Market Overview

Medical burden of wounds drives new technology investments

The increasing prevalence of chronic wounds is being driven by the sharp rise in diabetes and obesity


Types of wound	US prevalence (m)	Worldwide prevalence (m)	Healing time (days)	Estimated CAGR (2007-16e)
Surgical wounds	67	110.3	14	3.6%
Traumatic wounds	N/A	1.6	28	1.7%
Lacerations	N/A	20.4	14	1.2%
Burn wounds (outpatient)	1.3	3.4	21	1.0%
Burn wounds (medically treated)	N/A	6.5	21	1.3%
Burn wounds (hospitalised)	N/A	0.2	50	1.1%
Pressure ulcers	2.5	8.5	N/A	6.9%
Venous ulcers	2.5	12.5	N/A	6.7%
Diabetic ulcers	1.5	13.5	70-150	9.3%
Amputations	0.086	0.2	N/A	1.2%
Carcinomas	N/A	0.6	14	3.0%
Melanoma	N/A	0.1	14	3.29
Complicated skin cancer	N/A	0.1	28	3.19



U.S. Wound Care Market Overview


Prevalence of wounds

US prevalence of all wounds (8 million pa)



Source: BioMedGPS (2015)

U.S. prevalence of hard-to-heal wounds* (3.2 million pa)



Source: BioMedGPS (2015). Note: *<50% surface area reduction in four weeks



The dermaPACE® System meets the market need for better outcomes at lower cost

Key Industry Needs



BROADER ACCESS TO CARE



REDUCED COSTS




IMPROVED HEALTH
OUTCOMES




CARE EXPERIENCE



The dermaPACE®
System positions
SANUWAVE for large
revenue potential
across wound
indications in the
United States





¹ Rice et al. Diabetes Care 2014;37 ²: 651-658. 2Rice et al. J Med Econ 2014; 17 (5): 347-356. ³ National Pressure Ulcer Advisory Panel (INPUAP). Pressure Ulcer Awareness Day Proclamation. Available at: www.npuap.org/wp-content/uploads/2012/11/Proclamation-Pressure-Ulcer-Awa. ⁴Derived by combining the data provided within sources 1,2 &3 *Does not include work-loss costs, legal costs, prescription drug costs for Medicare patients, out-of-pocket costs paid by the patient, costs borne by supplemental insurers, and other indirect costs.




The dermaPACE® System positions **SANUWAVE** for continued success in large and emerging markets

Market Drivers

- Aging population
- Chronic illnesses
- Emerging middle class
- Clinical
 - practice/education •
- Innovation
- n Funding
 - Regulatory environment

Reach

Volume of wounds by geography (M) (Premium and mid-tier segments only)



Value of wounds by geography (\$M) (Premium and mid-tier segments only)



Source: Smith & Nephew (2015)



Strategy to Capture Growth Opportunities

Healthcare Industry
Needs Drive
Opportunities

Broader Access

Reduce Cost & Improve Efficiency

Improve Clinical
Outcomes and Patient
Experience

Sanuwave Strategies to Capture Growth

Drive Global Expansion

Deliver Economic Value

Accelerate Therapy Innovation

Sources of Growth

- U.S. launch of dermaPACE
- Sales coverage ramp up
- Enhanced commercialization infrastructure
- Emerging markets
- Value-added solutions and services that offer clinical and economic advantages
- AWC portfolio additions (M&A)
- New dermaPACE indications (5-fold DFU Market (see slide 14)
- PACE R&D new therapies (Multibillion market opportunity (see slide 14)



Market Opportunity with The dermaPACE® System

U.S Market

- Diabetic Foot Ulcers \$4B+ market size.
- 29 million people living with diabetes and 86 million pre-diabetics.
- 25% of diabetics will acquire a non-healing ulcer in their lifetime; ~3 million diabetic ulcers annually.
- Diabetic foot ulcers lead to over 50,000 amputations annually at a cost that is estimated to exceed \$5.1 billion annually.
- Hospitalization costs of ~\$20,000 for a patient with a DFU; ~\$70,000 for an amputation.

International Market

- Globally there are 382 million people living with diabetes and it is expected to reach 592 million by 2035, an increase of 55%.
- dermaPACE is CE Marked and currently marketed by independent distributors in Canada, Romania, Italy, S. Korea, Taiwan, Malaysia and Indonesia.
- dermaPACE can be licensed or joint ventured in these markets to speed market penetration while minimizing operating costs.

The international global wound care market of \$22 billion offers significant expansion opportunity for CE marked dermaPACE



The dermaPACE® System Treating Diabetic Foot Ulcers



Robust closure with extremely low recurrence rates



Non-invasive, convenient, and safe




Mechanism of action (MOA) allows:



Cost-effective



May be used as an adjunct therapy




Restored oxygenation to ischemic area

Accelerated tissue repair that may decrease long-term DFU complications





U.S. Market Strategy



Even Point




Assisted Living

Care

Growth Strategy

Seek relationships with qualified partners and JV/licensing agreements

- Address advanced wound care market large and growing
 - ✓ Domestic rollout of 2,000 placements; 500,000 treatments (DFU only) and greater than \$100 million in revenue in 5 years
 - ✓ With increased indication the number of treatments per year could reach 2,500,000
 - ✓ International placements and revenue could equal domestic over the same period
 - ✓ Combination therapies will drive increasing usage globally
- Serve other medical markets, orthopedics, plastic/cosmetic, vascular/cardiac
 - √ \$2 Billion Market Opportunity
- Expand to non-medical industrial applications (biofilm destruction, water cleaning, energy production). Working with major universities in proof of concept
 - √ \$2 Billion Market Opportunity






Business Model Transformation

Transform from a product company to a provider of comprehensive value propositions and solutions that address the wound care patient pathway










Global Clinical Studies

<u>Action</u>	<u>Sites</u>
Pharmacoeconomic	
• DFU2	12
New AWC	
• VLU	12+
 Pressure Ulcer 	12+
• ALU	12+
Dr. Siemionow	1
Vascularization/Perfusion/Dosing	
 Domestic/US 	2
 Global 	2
Surgical Incisions/Cosmetic	
 Domestic/US 	1
Combination Therapy	




At any given time we are engaged in multiple international case studies to treat wounds as well as other scientific studies. They range from biofilm, the Critical Limb Ischemia, stem cell growth, cardiac, and inflammatory response.



Intellectual Property (IP) Organic Growth


Number of Patents in 2006, 2012 and 2018



	<u>2006</u>	2012	2018
US Patents	14	18	
Foreign Patents	10	9	
US Appl(s)	11	9	
Foreign Appl(s)	2	10	
TOTAL	37	46	62
Percentage		24%	
Subject of Issued Patents	Orthopedics, Arthritis, Ischemia, Spinal, Lithotripsy, Device Design	Orthopedics, Arthritis, Ischemia, Spinal, Blood Sterilization, Device Design	



New Device Placements (Includes International) – Historical and 2019 Projection





Non-Medical Markets

Addressable opportunities covered by Patents

Energy Production

- Advanced Fracking
- Improved / Enhanced Oil Extraction Recovery

Food Industry

- Preservation
 - Milk
 - Fruit Juices
- Meat Tenderizing
- Meat Cleaning

Water

- Fracking Water Cleaning
- Industrial Water Cleaning
- Drinking Water Cleaning

Industrial Biofilms

- Biofilm Destruction
 - Industrial Equipment
 - Cosmetic/Food Industry Equipment
 - Monuments









Wound Care

Wound Care Industry Valuations and Comparison

Company Name	Ticker Symbol	Market Cap (as of 7/5/19)
Integra Life Sciences Holding Corp.	NASDAQ: IART	\$4.7B
Convatec Group Plc	LSE: CTEC	\$2.9B
Vericel Corporation	NASDAQ: VCEL	\$841M
Organogenesis	NASDAQ: ORGO	\$731M
Osiris Therapeutics Inc. ¹	NASDAQ: OSIR	\$656M
MiMedx Group Inc.	OTC MKTS: MDXG	\$559M
Mediwound Ltd.	NASDAQ: MDWD	\$89M
RenovoCare	OTC MKTS: RCAR	\$103M
SANUWAVE Health, Inc.	OTC MKTS: SNWV	\$24M
Shockwave Medical ³	NASDAQ: SWAV	\$1.5B
Soliton, Inc. ²	NASDAQ: SOLY	\$260M

Footnotes:

- 1 Acquired by Smith and Nephew
- 2- IPO February 19, 2019
- 3- IPO March 11, 2019



Select Financial Information

Cash and Cash Equivalents - March 31, 2019	\$98,946
Common Shares Outstanding	188M
Warrants	68M
Options Outstanding	33M
Notes Payable - Due December 31, 2018	\$6.8M ₍₁₎

(1) Due to HealthTronics, Inc. as part of original 2005 purchase price



Management Team

Kevin Richardson II, CEO and Chairman of the Board – Joined August 2005

Joined the Company as chairman of the board of directors in August of 2005. Brings a broad array of financial knowledge for healthcare information technology, financial services, business services and other industries. Since 2004, Mr. Richardson founded and has served as managing partner of Prides Capital LLC, an investment management firm.

Shri Parikh, President – Joined in 2018

20+ years experience in healthcare, medical device and wound care. Previously, Shri was with Molnlycke Health Care, where he held the title of Vice President, Sales and Marketing. Shri was also the Director of National Accounts at Stryker in Austin, TX, a leading medical technology company offering innovative products and services in Orthopaedics, Medical and Surgical Equipment, and Neurotechnology and Spine. Shri began his career in sales at Bristol-Myers Squibb and held various roles with increasing sales and corporate account responsibility at Guidant and St. Jude prior to joining Stryker.

Iulian Cioanta, Ph.D., Chief Technology and Science Officer – Joined in 2007

18+ years experience in medical device industry. Previously with Cordis Endovascular, a Johnson & Johnson company, Kensey Nash Corporation, ArgoMed Inc. and the Institute for the Design of Research Apparatuses.

Lisa Sundstrom, Chief Financial Officer—Joined in 2006

20+ years finance and accounting experience. Previously with Automatic Data Processing (ADP) and Mitsubishi Consumer Electronics.

Peter Stegagno, Chief Operating Officer-Joined in 2006

20+ years in medical device markets including manufacturing, design and development, quality assurance and international and domestic regulatory affairs.



Why Invest in SANUWAVE®

- ➤ The dermaPACE® System received FDA Clearance on 12/28/2017
- SANUWAVE® contracted with Premier Shockwave in the US as the distributor for the Veteran's Association and the Indian Health Reservation
- Internationally signed 15 new countries in 2018
- Equipment Finance agreement signed in US with NFS.
- Seasoned Management team
- Advanced wound care market growing 5%+ YOY
- ➤ USA DFU market is over \$4Billion annually
- Execution: 130 placements in 2019 will lead to rapid revenue increases
- Received CPT tracking code for billing to insurance carriers of the procedure



SANUVAVE®

Healing today. Curing tomorrow.

To be viewed by the world as a diverse compassionate global family that provides positive impact on life and environment, one shock at a time.

OTCQB: SNWV

SANUWAVE Health, Inc. 3360 Martin Farm Road, Suite 100 Suwanee, GA 30024

info@sanuwave.com

+1(770) 419-7525

